SynthesisThe oncologist2015
Practical management of bevacizumab-related toxicities in glioblastoma.
Synthesis in The oncologist, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 92 citations in OpenAlex.
- AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma.Neuro-oncology · 2016Trial
- Managing adverse events in patients with metastatic colorectal cancer receiving trifluridine/tipiracil in combination with bevacizumab.ESMO gastrointestinal oncology · 2025Review
- Diagnosis, clinical management, and emerging strategies for coronary artery disease in patients with cancer.American heart journal plus : cardiology research and practice · 2025Review
- Hemorrhagic and ischemic risks of anti-VEGF therapies in glioblastoma.Cancer gene therapy · 2025Review
- Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment.ESMO gastrointestinal oncology · 2025Article
- Bevacizumab‑associated intracerebral hemorrhage in patients with malignant glioma.Molecular and clinical oncology · 2025Article
- Intestinal perforation in recurrent cervical cancer following bevacizumab and pembrolizumab therapy: A case report.Medicine · 2025Article
- A promise of nose to brain delivery of bevacizumab intranasal sol-gel formulation substantiated in rat C6 glioma model.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Review
- Design, Synthesis, and Computational Evaluation of 3,4-Dihydroquinolin-2(Pharmaceuticals (Basel, Switzerland) · 2025Article
- Case report: Bevacizumab-induced cerebrovascular events: a case series report and literature review.Frontiers in oncology · 2025Article
- Review
- Machine learning application identifies plasma markers for proteinuria in metastatic colorectal cancer patients treated with Bevacizumab.Cancer chemotherapy and pharmacology · 2024Article
- Novel insights into cardiovascular toxicity of cancer targeted and immune therapies: Beyond ischemia with non-obstructive coronary arteries (INOCA).American heart journal plus : cardiology research and practice · 2024Article
- Development of Analytical Method for the Quantitation of Monoclonal Antibodies Solutions via Raman Spectroscopy: The Case of Bevacizumab.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Article
- Article
- Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials.Journal of pharmaceutical health care and sciences · 2024Article
- Renal Implications of Long-Term Systemic Bevacizumab for Recurrent Respiratory Papillomatosis.The Annals of otology, rhinology, and laryngology · 2024Article
- Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bevacizumab, currently an option for treatment of different types of tumors including glioblastoma, has a peculiar toxicity profile related to its antiangiogenic effect. Because some bevacizumab-related adverse events can be life threatening, it is important to identify risk factors and to establish treatment protocols to minimize treatment-related morbidity and mortality. In glioblastoma patients, the risk of developing certain side effects, such as gastrointestinal perforation, venous thromboembolism, and intracranial hemorrhages, is slightly higher than in patients treated with bevacizumab for other tumor types. We performed a systematic review of the side effects of bevacizumab and their incidence, causal mechanisms, and available treatments. Finally, we identified risk factors and proposed preventive and therapeutic measures for these adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.